MedTrace Logo

Treatment of Hypoparathyroidism With Subcutaneous PTH (1-84) Injections: Effects on Muscle Function and Quality of Life

NCT00730210 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2012-10-24

No results posted yet for this study

Summary

The aim of the study is to assess whether PTH (1-84) therapy posses advantages compared to conventional treatment in patients with hypoparathyroidism on muscle function, quality of life, calcium homeostasis, bone metabolism, and body composition.

Conditions

  • Hypoparathyroidism

Interventions

DRUG

a: PTH (1-84)

preotact 100 microgram subcutaneous a day in 6 months

DRUG

b:placebo

100 microgram placebo subcutaneous a day for 6 months

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Lars Rejnmark, MD,DrMed

  • Tanja Sikjær, MD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00730210 on ClinicalTrials.gov